Statement: the primary trial recorded less than 5 different Adverse Events .
Primary_evidence: Adverse Events 1:   Total: 4/31 (12.90%)   Bleeding  1/31 (3.23%)   Pain  2/31 (6.45%)   Dehydration  1/31 (3.23%)   Dyspnea  1/31 (3.23%)